Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R.

Ther Adv Med Oncol. 2011 Jul;3(4):171-84. doi: 10.1177/1758834011408636.

2.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
3.

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.

Smyth EC, Sclafani F, Cunningham D.

Onco Targets Ther. 2014 Jun 12;7:1001-14. doi: 10.2147/OTT.S44941. eCollection 2014. Review.

4.

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib.

Agwa ES, Ma PC.

Cancer Manag Res. 2014 Oct 4;6:397-404. doi: 10.2147/CMAR.S37345. eCollection 2014. Review.

5.

MET inhibitors in combination with other therapies in non-small cell lung cancer.

Padda S, Neal JW, Wakelee HA.

Transl Lung Cancer Res. 2012 Dec;1(4):238-53. doi: 10.3978/j.issn.2218-6751.2012.10.08. Review.

6.

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.

Yano S, Takeuchi S, Nakagawa T, Yamada T.

Cancer Sci. 2012 Jul;103(7):1189-94. doi: 10.1111/j.1349-7006.2012.02279.x. Epub 2012 May 9. Review.

7.

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R.

Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59. Review.

PMID:
11750879
8.

Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.

Landi L, Minuti G, D'Incecco A, Cappuzzo F.

Curr Opin Oncol. 2013 Mar;25(2):130-6. doi: 10.1097/CCO.0b013e32835daf37. Review.

PMID:
23385860
9.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
10.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Review.

PMID:
24636263
11.

MET as a target for treatment of chest tumors.

Cipriani NA, Abidoye OO, Vokes E, Salgia R.

Lung Cancer. 2009 Feb;63(2):169-79. doi: 10.1016/j.lungcan.2008.06.011. Epub 2008 Jul 30. Review.

12.

The emerging role of MET/HGF inhibitors in oncology.

Scagliotti GV, Novello S, von Pawel J.

Cancer Treat Rev. 2013 Nov;39(7):793-801. doi: 10.1016/j.ctrv.2013.02.001. Epub 2013 Feb 28. Review.

PMID:
23453860
13.

[MET receptor inhibition: Hope against resistance to targeted therapies?]

Hochart A, Leblond P, Le Bourhis X, Meignan S, Tulasne D.

Bull Cancer. 2017 Feb;104(2):157-166. doi: 10.1016/j.bulcan.2016.10.014. Epub 2016 Nov 15. Review. French.

PMID:
27863726
14.

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Christensen JG, Burrows J, Salgia R.

Cancer Lett. 2005 Jul 8;225(1):1-26. Epub 2004 Nov 11. Review.

PMID:
15922853
15.

MET overexpression and gene amplification in NSCLC: a clinical perspective.

Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F.

Lung Cancer (Auckl). 2013 Jun 18;4:15-25. doi: 10.2147/LCTT.S35168. eCollection 2013. Review.

16.

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Suda K, Mizuuchi H, Maehara Y, Mitsudomi T.

Cancer Metastasis Rev. 2012 Dec;31(3-4):807-14. doi: 10.1007/s10555-012-9391-7. Review.

PMID:
22736441
17.

MET targeted therapy for lung cancer: clinical development and future directions.

Feng Y, Ma PC.

Lung Cancer (Auckl). 2012 Aug 9;3:53-67. doi: 10.2147/LCTT.S23423. eCollection 2012. Review.

18.

Epidermal growth factor receptor: pathway, therapies, and pipeline.

Goffin JR, Zbuk K.

Clin Ther. 2013 Sep;35(9):1282-303. doi: 10.1016/j.clinthera.2013.08.007. Review.

PMID:
24054705
19.

MET signaling: novel targeted inhibition and its clinical development in lung cancer.

Feng Y, Thiagarajan PS, Ma PC.

J Thorac Oncol. 2012 Feb;7(2):459-67. doi: 10.1097/JTO.0b013e3182417e44. Review.

20.

Supplemental Content

Support Center